Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

X4 Pharmaceuticals

DB:48Q
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
48Q
DB
$150M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. The last earnings update was 28 days ago. More info.


Add to Portfolio Compare Print
  • X4 Pharmaceuticals has significant price volatility in the past 3 months.
48Q Share Price and Events
7 Day Returns
9.5%
DB:48Q
2.2%
DE Biotechs
7.2%
DE Market
1 Year Returns
-
DB:48Q
-9%
DE Biotechs
-14.3%
DE Market
48Q Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
X4 Pharmaceuticals (48Q) 9.5% 2.7% - - - -
DE Biotechs 2.2% 0.4% -23.6% -9% 16.2% -12.2%
DE Market 7.2% -3.5% -22% -14.3% -19.9% -25.7%
1 Year Return vs Industry and Market
  • No trading data on 48Q.
  • No trading data on 48Q.
Price Volatility
Industry
5yr Volatility vs Market

48Q Value

 Is X4 Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for X4 Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €8.05.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for X4 Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are X4 Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:48Q PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-4.63
NasdaqCM:XFOR Share Price ** NasdaqCM (2020-04-08) in USD $9.3
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 42.02x
Germany Market PE Ratio Median Figure of 403 Publicly-Listed Companies 17.05x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of X4 Pharmaceuticals.

DB:48Q PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:XFOR Share Price ÷ EPS (both in USD)

= 9.3 ÷ -4.63

-2.01x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • X4 Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • X4 Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does X4 Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:48Q PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.01x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
-0.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for X4 Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on X4 Pharmaceuticals's assets?
Raw Data
DB:48Q PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $8.01
NasdaqCM:XFOR Share Price * NasdaqCM (2020-04-08) in USD $9.3
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.4x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.5x
DB:48Q PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:XFOR Share Price ÷ Book Value per Share (both in USD)

= 9.3 ÷ 8.01

1.16x

* Primary Listing of X4 Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • X4 Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess X4 Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. X4 Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

48Q Future Performance

 How is X4 Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-0.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is X4 Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare X4 Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare X4 Pharmaceuticals's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare X4 Pharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:48Q Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:48Q Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts -0.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 37.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.3%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.2%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:48Q Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:48Q Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 74 -26 -46 6
2023-12-31 37 -54 -69 6
2022-12-31 9 -59 -77 7
2021-12-31 5 -55 -63 7
2020-12-31 0 -54 -58 7
2020-04-09
DB:48Q Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -48 -53
2019-09-30 -46 -55
2019-06-30 -39 -46
2019-03-31 -31 -40
2018-12-31 -25 -36
2018-09-30 -23 -31
2017-12-31 -21 -25

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • X4 Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if X4 Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:48Q Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from X4 Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:48Q Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -1.64 1.43 -4.40 6.00
2023-12-31 -2.59 -1.19 -5.30 6.00
2022-12-31 -3.24 -1.99 -5.00 7.00
2021-12-31 -2.97 -1.47 -3.65 7.00
2020-12-31 -3.29 -2.95 -3.60 7.00
2020-04-09
DB:48Q Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -4.63
2019-09-30 -4.60
2019-06-30 -5.55
2019-03-31 -7.71
2018-12-31 -79.10
2018-09-30 -19.83
2017-12-31 -54.57

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if X4 Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess X4 Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
X4 Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

48Q Past Performance

  How has X4 Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare X4 Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • X4 Pharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare X4 Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare X4 Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
X4 Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from X4 Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:48Q Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -53.40 16.64 30.16
2019-09-30 -54.60 17.79 27.09
2019-06-30 -46.24 15.80 24.66
2019-03-31 -39.67 12.86 20.56
2018-12-31 -36.31 8.74 20.35
2018-09-30 -30.72 6.80 19.24
2017-12-31 -24.99 5.18 17.07
2016-12-31 -20.87 5.13 12.76

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if X4 Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if X4 Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if X4 Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess X4 Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
X4 Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

48Q Health

 How is X4 Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up X4 Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • X4 Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • X4 Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of X4 Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 6.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from X4 Pharmaceuticals Company Filings, last reported 3 months ago.

DB:48Q Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 129.22 20.10 126.18
2019-09-30 79.11 19.99 76.25
2019-06-30 96.17 25.90 90.18
2019-03-31 29.44 18.66 22.30
2018-12-31 -7.46 9.83 8.13
2018-09-30 0.26 4.63 9.84
2017-12-31 17.60 6.05 26.68
2016-12-31 13.04 0.00 15.16
  • X4 Pharmaceuticals's level of debt (15.6%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if X4 Pharmaceuticals's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • X4 Pharmaceuticals has sufficient cash runway for 2.6 years based on current free cash flow.
  • X4 Pharmaceuticals has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 33.5% each year.
X
Financial health checks
We assess X4 Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. X4 Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

48Q Dividends

 What is X4 Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from X4 Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of X4 Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate X4 Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate X4 Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:48Q Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:48Q Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as X4 Pharmaceuticals has not reported any payouts.
  • Unable to verify if X4 Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of X4 Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as X4 Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of X4 Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess X4 Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can X4 Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. X4 Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

48Q Management

 What is the CEO of X4 Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paula Ragan
AGE 48
TENURE AS CEO 5.8 years
CEO Bio

Dr. Paula Ragan, Ph.D. is a Founder of X4 Pharmaceuticals Inc. and serves as its Chief Executive Officer, President and Director since July 2014 and its Secretary since March 13, 2019. Dr. Ragan consulted as Chief Business Officer of Lysosomal Therapeutics Inc August 2012 to September 2014. Prior to that, from January 2007 to August 2012, Dr. Ragan held leadership roles in corporate development and operations at Genzyme Corporation, a Sanofi company, where she led strategic partnering efforts for Genzyme’s Rare Disease business and headed the supply chain planning for Genzyme’s flagship commercial products. Dr. Ragan served as Senior Director, Corporate Development of Hydra Biosciences Inc. Dr. Ragan joined Hydra Biosciences from Oscient Corporation. She served as Senior Director of Corporate Development at Hydra Biosciences, Inc. During her years at Oscient, she played an instrumental role in business development transactions with a focus on in and out-licensing technologies and products. Her efforts led to several successful partnerships including a strategic alliance with Amgen and a corporate licensing agreement with Aventis. Additionally, she contributed to the product launch efforts for the manufacturing, sales and marketing of Factive, an FDA approved antibiotic. She also held positions at Celera Corporations (formerly Celera Genomics) where her strategic analysis identified Axys Pharmaceuticals as an M&A opportunity; Celera acquired Axys in 2001. She held positions at Pfizer Inc. and UroMed Corporation. Dr. Ragan received her Ph.D. from Massachusetts Institute of Technology and completed a Post-Doctoral fellowship at Harvard Medical School. She earned her B.S. degree magna cum laude in Mechanical Engineering at Tufts University.

CEO Compensation
  • Insufficient data for Paula to compare compensation growth.
  • Insufficient data for Paula to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the X4 Pharmaceuticals management team in years:

1.3
Average Tenure
48
Average Age
  • The average tenure for the X4 Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Paula Ragan

TITLE
Founder
AGE
48
TENURE
5.8 yrs

Renato Skerlj

TITLE
Founder

Adam Mostafa

TITLE
CFO, Treasurer & Assistant Secretary
AGE
39
TENURE
1.6 yrs

Mary DiBiase

TITLE
Senior Vice President of Technical Operations & Quality
TENURE
0.4 yrs

Derek Meisner

TITLE
General Counsel
AGE
48
TENURE
1.3 yrs

Ronny Mosston

TITLE
Senior Vice President of Human Resources

Bob Arbeit

TITLE
Senior Vice President of Clinical Development and Translational Research
AGE
71

Nic Scalfarotto

TITLE
Senior VP of Regulatory Affairs & Program Management
TENURE
0.4 yrs
Board of Directors Tenure

Average tenure and age of the X4 Pharmaceuticals board of directors in years:

4
Average Tenure
56
Average Age
  • The tenure for the X4 Pharmaceuticals board of directors is about average.
Board of Directors

Mike Wyzga

TITLE
Chairman of the Board
AGE
64
TENURE
1.8 yrs

Paula Ragan

TITLE
Founder
AGE
48
TENURE
5.8 yrs

Renato Skerlj

TITLE
Founder

Davie McGirr

TITLE
Director
AGE
65
TENURE
1.1 yrs

Gary Bridger

TITLE
Director
AGE
56
TENURE
1.1 yrs

Alison Lawton

TITLE
Member of Corporate Advisory Board
AGE
58
TENURE
4 yrs

Keith Flaherty

TITLE
Member of Corporate Advisory Board
AGE
48
TENURE
4 yrs

Howard Pien

TITLE
Member of Corporate Advisory Board
AGE
61
TENURE
4 yrs

Mike Vasconcelles

TITLE
Member of Corporate Advisory Board
AGE
55
TENURE
4 yrs

René Russo

TITLE
Director
AGE
44
TENURE
1.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess X4 Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. X4 Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

48Q News

Simply Wall St News

48Q Company Info

Description

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Details
Name: X4 Pharmaceuticals, Inc.
48Q
Exchange: DB
Founded: 2014
$137,986,718
16,134,495
Website: http://www.x4pharma.com
Address: X4 Pharmaceuticals, Inc.
955 Massachusetts Avenue,
4th Floor,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM XFOR Common Shares Nasdaq Capital Market US USD 14. Mar 2019
DB 48Q Common Shares Deutsche Boerse AG DE EUR 14. Mar 2019
Number of employees
Current staff
Staff numbers
58
X4 Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 03:32
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/08
Last earnings filing: 2020/03/12
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.